List of Excipients in Branded Drug BEXAGLIFLOZIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Golden State Medical Supply Inc	BEXAGLIFLOZIN	bexagliflozin	51407-918	CELLULOSE, MICROCRYSTALLINE	2041-10-05
Golden State Medical Supply Inc	BEXAGLIFLOZIN	bexagliflozin	51407-918	FD&C BLUE NO. 1	2041-10-05
Golden State Medical Supply Inc	BEXAGLIFLOZIN	bexagliflozin	51407-918	GLYCERYL DIBEHENATE	2041-10-05
Golden State Medical Supply Inc	BEXAGLIFLOZIN	bexagliflozin	51407-918	INDIGOTINDISULFONATE SODIUM	2041-10-05
Golden State Medical Supply Inc	BEXAGLIFLOZIN	bexagliflozin	51407-918	LACTOSE MONOHYDRATE	2041-10-05
Golden State Medical Supply Inc	BEXAGLIFLOZIN	bexagliflozin	51407-918	MAGNESIUM STEARATE	2041-10-05
Golden State Medical Supply Inc	BEXAGLIFLOZIN	bexagliflozin	51407-918	POLOXAMER 188	2041-10-05

Bexagliflozin Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Bexagliflozin, marketed in the United States as Brenzavvy, is a once-daily oral sodium-glucose cotransporter 2 inhibitor for adults with type 2 diabetes. Its commercial opportunity is concentrated in low-cost oral solid-dose manufacturing, differentiated excipient systems, fixed-dose combinations, and supply-chain economics rather than in biologic formulation or biosimilar development. The current product uses a conventional immediate-release tablet platform, leaving room for formulation suppliers to pursue manufacturability, stability, patient acceptability, and combination-product opportunities.[1]

What is bexagliflozin and how is Brenzavvy formulated?

Bexagliflozin is a small-molecule SGLT2 inhibitor administered as a 20 mg oral tablet once daily. The FDA-approved product is Brenzavvy, developed by TheracosBio and approved under NDA 214373.[1,2]

The product is an immediate-release, film-coated tablet. Public labeling identifies inactive ingredients used in the tablet and coating, including standard pharmaceutical excipients such as lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, and film-coating components.[1,3]

Formulation attribute	Brenzavvy profile
Active ingredient	Bexagliflozin
Strength	20 mg
Dosage form	Oral film-coated tablet
Release profile	Immediate release
Administration	Once daily
FDA pathway	New drug application
Product	Brenzavvy
Sponsor	TheracosBio
Primary therapeutic area	Type 2 diabetes
Primary formulation opportunity	Cost-efficient, robust oral solid dosage

The label does not indicate a modified-release system, lipid formulation, nanocrystal technology, gastroretentive delivery system, or other complex delivery platform. The current excipient architecture is therefore compatible with conventional high-volume tableting and coating equipment.

What excipients are used in Brenzavvy tablets?

The principal excipient functions are conventional and commercially established.

Excipient category	Likely function in the product
Lactose monohydrate	Diluent and tablet-bulk agent
Microcrystalline cellulose	Dry-binder, filler, and compression aid
Croscarmellose sodium	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant
Film-coating excipients	Surface protection, appearance, swallowability, and handling

The formulation indicates a standard direct-compression or closely related oral solid-dose strategy. Microcrystalline cellulose can provide compactibility, while croscarmellose sodium supports tablet breakup and drug release. Colloidal silicon dioxide can improve powder flow, an important factor when the active pharmaceutical ingredient has poor flow or electrostatic behavior. Magnesium stearate reduces tooling friction but requires control because excessive lubrication can reduce tablet tensile strength and slow disintegration.

Lactose introduces an important commercial consideration. Lactose-containing products require management of excipient compatibility, moisture, particle-size distribution, and patient labeling. A lactose-free alternative could be commercially relevant if it maintains dissolution, hardness, friability, and manufacturing throughput.

What excipient strategies could improve bexagliflozin manufacturing?

The most practical opportunity is optimization of a conventional immediate-release tablet rather than replacement with a high-complexity delivery system.

Direct-compression optimization

A direct-compression platform could reduce processing steps, solvent use, and production cost. The development targets would include:

• improved powder flow;
• reduced segregation between bexagliflozin and excipients;
• lower tablet-weight variability;
• robust hardness across commercial press speeds;
• rapid disintegration;
• consistent dissolution across scale;
• reduced sticking and picking during compression.

Co-processed excipients combining filler, binder, and flow-enhancing properties could reduce the number of formulation components. Examples include silicified microcrystalline cellulose and engineered multifunctional excipients. Any substitution would require comparative dissolution, impurity, stability, and bioequivalence assessment.

Lactose-free formulation

A lactose-free tablet could use mannitol, dibasic calcium phosphate, starch-based fillers, or alternative grades of microcrystalline cellulose. Mannitol may improve mouthfeel and provide a differentiated platform for orally disintegrating or chewable products, although those dosage forms would require new development work and potentially additional regulatory support.

Dibasic calcium phosphate could improve compactibility and reduce moisture sensitivity, but its density and brittle fracture behavior may alter blend uniformity and tablet performance. The commercial case depends on whether the resulting process is more robust than the current lactose-based formulation.

Moisture and stability control

SGLT2 inhibitor tablets must be evaluated for chemical stability, polymorphic behavior, blend uniformity, and dissolution after accelerated storage. Excipient moisture content, water activity, and packaging permeability are central variables.

A higher-barrier blister or bottle configuration could reduce dependence on desiccants and provide better stability in humid markets. Commercial opportunities exist for suppliers of:

• low-moisture excipients;
• high-barrier film and foil systems;
• desiccant closures;
• moisture-scavenging bottles;
• package-integrated stability monitoring.

The value proposition is strongest in markets with high humidity, weak cold-chain infrastructure, or long distribution routes.

What formulations are protected by bexagliflozin patents?

Bexagliflozin intellectual property may cover the active compound, related chemical intermediates, pharmaceutical compositions, therapeutic uses, and manufacturing processes. Excipient-level substitutions are not automatically free of patent risk. A formulation that uses a different filler or disintegrant can still fall within a composition-of-matter, pharmaceutical-composition, or method-of-treatment claim.

The commercial diligence should separate four categories:

1. active-ingredient patents;
2. formulation and pharmaceutical-composition patents;
3. method-of-use patents;
4. manufacturing and intermediate patents.

Public FDA labeling does not provide a complete patent analysis. Current patent numbers, expiration dates, Orange Book listings, pediatric exclusivity, terminal disclaimers, and any Paragraph IV certifications must be confirmed against the FDA Orange Book and the relevant USPTO records before a launch or licensing decision.[4,5]

Does bexagliflozin have biosimilar risk?

No. Bexagliflozin is a small molecule, so the relevant competitive pathway is an abbreviated new drug application, not a biosimilar application. Generic applicants would generally need to address bioequivalence, pharmaceutical equivalence, labeling, and any listed patent certifications under the Hatch-Waxman framework.

When does bexagliflozin lose exclusivity?

Brenzavvy received FDA approval in January 2023. New chemical entity exclusivity generally provides five years of FDA approval protection for an eligible active ingredient, subject to statutory exceptions. On that basis, the NCE period would generally extend into January 2028, although the exact date should be confirmed from FDA exclusivity records.[1,4]

Patent protection may extend beyond regulatory exclusivity. A generic applicant could submit an ANDA before patent expiration and certify against listed patents, creating a potential Paragraph IV dispute. Patent-term-extension eligibility, patent listing status, and any pediatric extension can materially alter the earliest lawful generic launch date.

Exclusivity issue	Commercial effect
NCE exclusivity	Blocks certain ANDA submissions during the statutory period
Listed patents	Can delay approval or create Paragraph IV litigation
Patent-term extension	May extend protection for qualifying regulatory delay
Pediatric exclusivity	Can add six months to qualifying protections
Formulation patents	May protect specific dosage forms or excipient systems
Method-of-use patents	May affect labeling and carve-out strategy

What is the Orange Book status of Brenzavvy?

The Orange Book is the controlling public source for listed patents and regulatory exclusivity associated with an approved small-molecule product.[4] Brenzavvy’s regulatory and patent position should be assessed using the current FDA Orange Book entry rather than historical product databases.

The key diligence questions are:

• Is Brenzavvy listed under the current NDA?
• Which patents are listed against the product?
• Are the patents drug-substance, drug-product, or method-of-use patents?
• Do any listed patents have terminal disclaimers?
• Is pediatric exclusivity present?
• Has any ANDA applicant submitted a Paragraph IV certification?
• Has TheracosBio sued within the applicable statutory period?

A formulation supplier should not assume that an excipient substitution avoids patent exposure. The relevant question is whether the proposed product practices a valid claim, not whether the excipient list differs from the reference product.

Which companies compete with bexagliflozin?

Bexagliflozin competes in a crowded SGLT2 inhibitor market.

Drug	Brand	Company or principal commercial sponsor	Key competitive position
Bexagliflozin	Brenzavvy	TheracosBio	Newer entrant with a low-cost commercial positioning
Empagliflozin	Jardiance	Boehringer Ingelheim and Eli Lilly	Strong cardiovascular and renal positioning
Dapagliflozin	Farxiga	AstraZeneca	Broad diabetes, heart-failure, and kidney-disease use
Canagliflozin	Invokana	Johnson & Johnson	Established SGLT2 product with cardiovascular and renal history
Ertugliflozin	Steglatro	Merck and Pfizer	Smaller SGLT2 franchise

The largest commercial barrier is not tableting complexity. It is market access. Jardiance and Farxiga have substantial prescriber familiarity, cardiovascular and renal outcome data, payer coverage, and combination-product presence. A lower-cost bexagliflozin product must compete through net price, formulary positioning, distribution, adherence, and potential expansion into combination therapy.

What commercial opportunities exist for bexagliflozin excipients?

Excipient supply

The most immediate opportunity is supply of qualified, cost-efficient materials for a conventional tablet. Suppliers can compete on:

• global availability;
• low extractables and leachables risk;
• consistent particle-size distribution;
• low bioburden;
• compendial compliance;
• reliable documentation;
• dual sourcing;
• price stability;
• technical support during scale-up.

For a value-oriented diabetes product, excipient cost is a small part of total product cost, but supply interruption or batch failure can have a disproportionate commercial effect.

Co-processed excipients

A co-processed filler-binder-disintegrant platform could reduce raw-material count and simplify process validation. The strongest target would be a formulation that preserves rapid dissolution while improving high-speed tableting and reducing capping or sticking.

Fixed-dose combinations

Bexagliflozin could be evaluated in combinations with metformin, a dipeptidyl peptidase-4 inhibitor, or another antihyperglycemic agent. Fixed-dose combinations create opportunities for:

• bilayer tablets;
• multilayer compression;
• separate granulation of incompatible actives;
• barrier layers;
• moisture-control systems;
• modified release for the partner active;
• tablet-size reduction.

Combination products can raise excipient complexity substantially. A bilayer tablet, for example, may require separate lubrication systems, layer-weight controls, and interfacial strength testing. The product must also demonstrate dissolution performance for each active.

Patient-centric dosage forms

Orally disintegrating, chewable, or smaller-dose presentations could target patients with swallowing difficulty or adherence barriers. These products would need evidence that the active is suitable for the proposed dosage form and that taste, dose uniformity, mechanical strength, and stability are acceptable.

This is a higher-risk opportunity than standard tablet optimization because it may require new clinical bridging, new manufacturing controls, and a separate regulatory strategy.

International markets

Bexagliflozin’s commercial potential may be stronger in markets where SGLT2 access is constrained by price. Excipient systems should be designed for regional raw-material availability and climatic-zone stability. A formulation dependent on one specialized excipient or a narrow particle-size grade could create avoidable geographic supply risk.

What manufacturing and IP barriers affect generic entry?

Generic entry risks fall into three groups.

First, active-ingredient access may be constrained by patents covering synthesis, intermediates, crystalline forms, or purification. Second, listed patents may cover pharmaceutical compositions, dosage forms, or methods of use. Third, regulatory requirements may make a nominally simple tablet expensive to reproduce if the reference product has narrow dissolution or stability specifications.

Generic developers will likely prioritize:

• a bioequivalent immediate-release tablet;
• excipient substitutions that avoid unnecessary patent overlap;
• a Paragraph IV strategy where justified;
• a section viii label carve-out for protected methods of use;
• a manufacturing process with fewer unit operations;
• a formulation that is stable without specialized packaging.

A formulation that uses common excipients may reduce supply risk but does not eliminate patent risk. A formulation with novel excipient ratios or a new dosage form may create separate intellectual-property value while increasing regulatory and litigation exposure.

How strong is the commercial patent estate for Brenzavvy?

Bexagliflozin’s commercial protection should be viewed as a layered system rather than a single expiration date. The active compound and regulatory exclusivity provide the initial protection. Later value depends on listed patents, method-of-use claims, manufacturing rights, and commercial execution.

The estate is commercially stronger if TheracosBio has:

• composition-of-matter protection extending beyond NCE exclusivity;
• valid and Orange Book-listed drug-product patents;
• enforceable renal or cardiovascular method claims;
• manufacturing patents that constrain low-cost API supply;
• settlement agreements that delay authorized or independent generic entry.

The estate is weaker if protection relies mainly on short-dated formulation claims, narrow method-of-use claims, or patents vulnerable to written-description, enablement, obviousness, or claim-construction challenges.

No public record cited here establishes a current Paragraph IV lawsuit, generic settlement, or authorized-generic agreement affecting Brenzavvy. Those matters require confirmation from current FDA, court, and company filings before being used in a transaction model.

Key Takeaways

• Brenzavvy is a conventional 20 mg immediate-release film-coated tablet.
• Its excipient platform supports standard, scalable oral solid-dose manufacturing.
• The best near-term opportunities are co-processed excipients, lactose-free alternatives, moisture-control systems, and cost-efficient global supply.
• Fixed-dose combinations create a larger formulation opportunity but require more complex development and regulatory work.
• Bexagliflozin faces generic, not biosimilar, competition.
• FDA NCE exclusivity from the January 2023 approval generally points to protection into January 2028, subject to confirmation of the official exclusivity record.
• Patent and Orange Book analysis must distinguish active-ingredient, formulation, method-of-use, and manufacturing claims.
• The principal commercial challenge is competition from entrenched SGLT2 products with cardiovascular, renal, payer, and combination-product advantages.

FAQs

Can lactose be replaced in a bexagliflozin tablet?

Yes, lactose can potentially be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate, or another suitable filler. The substitute must support bioequivalence, dissolution, stability, content uniformity, and acceptable compression performance.

Is an excipient supplier likely to receive patent protection for a bexagliflozin formulation?

Potentially. Protection may arise from a novel excipient ratio, particle engineering approach, dosage form, stability improvement, manufacturing process, or fixed-dose combination. Patentability depends on novelty, nonobviousness, enablement, and claim scope.

Could bexagliflozin be developed as an orally disintegrating tablet?

Potentially, but the product would require evaluation of taste, disintegration, dose uniformity, mechanical strength, moisture sensitivity, dissolution, and regulatory bridging. It would be a higher-complexity opportunity than conventional tablet optimization.

What packaging is most relevant for bexagliflozin tablets?

High-barrier blister packaging, moisture-resistant bottles, desiccant systems, and low-permeability closures are the principal options. The preferred system depends on stability data, distribution climate, package cost, and market requirements.

Does a generic bexagliflozin product need to use the same excipients as Brenzavvy?

No. An ANDA applicant may use different inactive ingredients if the product remains pharmaceutically equivalent, bioequivalent, stable, manufacturable, and compliant with FDA requirements. The applicant must also address any relevant patent certifications and labeling restrictions.

References

1. U.S. Food and Drug Administration. (2023). Brenzavvy (bexagliflozin) prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2023). NDA 214373: Brenzavvy approval information. https://www.accessdata.fda.gov
3. DailyMed. (2023). Brenzavvy: Bexagliflozin tablet, film coated. National Library of Medicine. https://dailymed.nlm.nih.gov
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda
5. U.S. Food and Drug Administration. (1984). Drug Price Competition and Patent Term Restoration Act. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda-grace-period-guidance-documents